# A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

> **NCT05950997** · NA · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 89 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT05950997
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-16
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-09-30
- **Target enrollment:** 89 (ESTIMATED)
- **Last updated:** 2024-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05950997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05950997, "A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05950997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*